What is the management for a retained placenta with a contracted uterus?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 22, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Retained Placenta with Contracted Uterus

For a retained placenta with a contracted uterus (placenta adherens), manual removal under anesthesia remains the definitive treatment at 30-60 minutes postpartum, but intraumbilical oxytocin injection (30 IU in 30 mL saline) can reduce the need for manual removal by approximately 20% and should be attempted first. 1

Understanding the Pathophysiology

A contracted uterus with retained placenta indicates placenta adherens—failed contraction of the retro-placental myometrium preventing placental separation, rather than a trapped placenta (which involves cervical constriction) or placenta accreta (abnormal placental invasion). 2, 1 This distinction is critical because the treatments differ fundamentally:

  • Placenta adherens requires uterotonics to contract the retro-placental myometrium 2
  • Trapped placenta requires uterine relaxants (nitroglycerin or terbutaline) to resolve cervical constriction 3, 4
  • Administering uterotonics systemically for placenta adherens can paradoxically worsen a trapped placenta by increasing cervical tone 2

Initial Medical Management (Before 30 Minutes)

Intraumbilical Oxytocin Injection

  • Administer 30 IU oxytocin in 30 mL saline via umbilical vein injection as first-line medical therapy 1
  • This approach may reduce the need for manual removal by approximately 20% 1
  • Low-certainty evidence suggests oxytocin solution via umbilical vein might slightly reduce manual removal compared to expectant management (RR 0.73,95% CI 0.56 to 0.95) 5
  • The mechanism bypasses systemic circulation and delivers oxytocin directly to the retro-placental myometrium 2

Timing Considerations

  • Do not attempt manual removal before 30 minutes postpartum unless severe uncontrollable hemorrhage occurs 3, 1
  • The World Health Organization defines retained placenta as failure of spontaneous delivery more than 30 minutes after fetal expulsion 3
  • Manual removal should be performed at 30-60 minutes postpartum if medical management fails 1

Definitive Management: Manual Removal

Anesthetic Approach

If an epidural catheter is already in place and the patient is hemodynamically stable, epidural anesthesia is the preferred technique for manual removal. 3

  • Neuraxial anesthesia (epidural or spinal) is first-line when the patient is hemodynamically stable 3, 6
  • Assess hemodynamic status thoroughly before administering neuraxial anesthesia—check for active bleeding, blood pressure stability, and signs of hypovolemia 3, 6
  • Aspiration prophylaxis should be considered due to increased aspiration risk in the immediate postpartum period 3

When General Anesthesia is Preferred

In cases involving major maternal hemorrhage with hemodynamic instability, general anesthesia with endotracheal intubation is preferable to neuraxial anesthesia. 3, 6

  • Major hemorrhage (>1000 mL or hemodynamic instability) is an indication for general anesthesia 3
  • Have ephedrine readily available to treat hypotension during any anesthetic technique 4

Uterine Relaxation (If Needed)

If the uterus remains contracted and prevents manual removal despite anesthesia:

Administer nitroglycerin in incremental IV doses of 50-100 mcg boluses or sublingual spray to achieve uterine relaxation while minimizing hypotension. 3, 4

  • Nitroglycerin is an alternative to terbutaline or halogenated general anesthetic agents for uterine relaxation 3, 4
  • Monitor blood pressure continuously during administration 4
  • This is a critical distinction: uterine relaxation is only needed if the contracted uterus prevents access during manual removal, not as primary treatment for placenta adherens 3

Postpartum Hemorrhage Prevention

Active Management of Third Stage

  • Administer 5-10 IU oxytocin slow IV or IM at time of shoulder release or immediate postpartum to reduce PPH incidence 3
  • Active management (prophylactic uterotonics, controlled cord traction after placental separation) reduces PPH risk compared to expectant management (RR 0.38,95% CI 0.32 to 0.46) 3

If Hemorrhage Occurs

  • Administer 1 g tranexamic acid IV within 1-3 hours of bleeding onset to reduce bleeding-related mortality 3
  • Methylergonovine can be used for routine management of uterine atony and hemorrhage following placental delivery 7

Critical Pitfalls to Avoid

  1. Do not attempt forced placental removal without anesthesia—this causes profuse hemorrhage and is strongly discouraged 3
  2. Do not administer systemic uterotonics if you suspect trapped placenta (cervical constriction)—this worsens the condition 2
  3. Do not delay manual removal beyond 60 minutes unless the patient is stable and medical management is showing progress 1
  4. Do not use neuraxial anesthesia in hemodynamically unstable patients—general anesthesia is safer 3, 6
  5. Do not confuse the need for uterine relaxation during manual removal with primary treatment—a contracted uterus with retained placenta needs oxytocics first, not relaxants 2

Evidence Limitations

Current evidence for systemic uterotonics (sulprostone, misoprostol) versus placebo shows they may result in little to no difference in manual removal rates (RR 0.82,95% CI 0.54 to 1.27), PPH, or blood transfusion requirements 8. The most promising intervention remains intraumbilical oxytocin, though evidence is low-certainty 5. Manual removal remains the gold standard when medical management fails 1.

References

Research

The retained placenta.

Best practice & research. Clinical obstetrics & gynaecology, 2008

Research

Retained placenta: will medical treatment ever be possible?

Acta obstetricia et gynecologica Scandinavica, 2016

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Nitroglycerin Safety and Efficacy in Pregnancy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Umbilical vein injection for management of retained placenta.

The Cochrane database of systematic reviews, 2021

Guideline

Anesthesia Management for Placenta Previa

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Uterotonics for management of retained placenta.

The Cochrane database of systematic reviews, 2024

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.